What’s Next for Larotrectinib? - 102164

Spotlight
Video

What’s Next for Larotrectinib?

Loading........
Description: David Michael Hyman, MD of Memorial Sloan-Kettering talks of his hopes for LOXO-101 in future clinical practice and clinical trials at the 2017 ASCO Annual Meeting in Chicago, IL.

LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers
Shared By : AnnualMeeting2017
Posted on : 06/06/17
Added : 9 months ago
Category : Other



Recommended

Nothing found.

More From AnnualMeeting2017

Nothing found.